Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ:MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the Class Period from October 10, 2025, to November 12, 2025 [7]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [7]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [7]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [7]. Stock Performance - Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share prior to November 12, 2025, despite no fundamental news justifying such a rise [7]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [7]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the necessary information to lift the suspension [7].
Bragar Eagel & Squire, P.C. Urges Charming Medical (MCTA) Investors With Large Losses to Contact the Firm Before the February 17th Class Action Lead Plaintiff Deadline